How to improve clotting factors depletion in double-filtration plasmapheresis

被引:4
作者
Naciri Bennani, Hamza [1 ]
Marlu, Raphael [2 ,3 ]
Terrec, Florian [1 ]
Motte, Lionel [1 ]
Seyve, Landry [2 ]
Chevallier, Eloi [1 ]
Malvezzi, Paolo [1 ]
Jouve, Thomas [4 ]
Rostaing, Lionel [1 ,4 ]
Noble, Johan [1 ]
机构
[1] Grenoble Univ Hosp, Nephrol Hemodialysis Apheresis & Kidney Transplan, Grenoble, France
[2] Grenoble Univ Hosp, Hemostasis Lab, Grenoble, France
[3] Grenoble Alpes Univ, Grenoble, France
[4] Univ Grenoble Alpes, Grenoble, France
关键词
clotting factors; double-filtration plasmapheresis; fibrinogen; plasma filter; THERAPEUTIC PLASMA-EXCHANGE; APHERESIS;
D O I
10.1002/jca.21928
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Double-filtration plasmapheresis (DFPP), a selective therapeutic apheresis, can deplete pathogenic antibodies/substances, but also important coagulation factors. Aim To determine if the use of a separator filter with different characteristics (CascadefloEC-50 W) as compared to the reference filter (PlasmafloOP-08 W) is as efficient in terms of immunoglobulin loss, but can reduce coagulation factor losses and have similar tolerability. Patients/Methods This is a single-center prospective study including 14 patients divided into two groups (7 each): that is, group1 = CascadefloEC-50 W and group2 = PlasmafloOP-08 W. We measured immunoglobulins, lipid profiles, blood-cell counts, hemostasis (prothrombin time, activated partial thromboplastin time), coagulation factors, and natural anticoagulants at before and after the first DFPP-session. Results In group 1, the loss of coagulation factors was significantly reduced as compared to group 2 for proteins with a molecular weight of >150 kDa: there was, respectively, an average decrease of 70% vs 31% for fibrinogen (P = 0.004), 66% vs 21% for factor V (P = 2.16e-07), 60% vs 32% for factor XI (P = 6.96e-06), 75% vs 17% for XIII-antigen (P = 0.0002), and 47% vs 0% for VWF-antigen(P = 0.02). The decrease in post-session IgG was, on average, 45% in group 1 and 50% in group 2 (P = 0.13). Those results remained significant even when adjusted to the treated-plasma volume and the pre-DFPP factor values. Conclusion DFPP, using a CascadefloEC-50W as a first-filter, reduces efficiently IgGs similarly to PlasmafloOP-08W but spares clotting factors.
引用
收藏
页码:766 / 774
页数:9
相关论文
共 25 条
  • [1] Treatment of refractory myasthenia gravis by double-filtration plasmapheresis and rituximab: A case series of nine patients and literature review
    Bennani, Hamza N.
    Lagrange, Emmeline
    Noble, Johan
    Malvezzi, Paolo
    Motte, Lionel
    Chevallier, Eloi
    Rostaing, Lionel
    Jouve, Thomas
    [J]. JOURNAL OF CLINICAL APHERESIS, 2021, 36 (03) : 348 - 363
  • [2] Isoagglutinin removal by plasma centrifugation or filtration (single or double): A prospective study in a single center
    Bennani, Hamza Naciri
    Noble, Johan
    Chevallier, Eloi
    Terrec, Florian
    Motte, Lionel
    Giroux-Lathuile, Claudine
    Bugnazet, Mathilde
    Imerzoukene, Farida
    Janbon, Benedicte
    Malvezzi, Paolo
    Rostaing, Lionel
    Jouve, Thomas
    [J]. JOURNAL OF CLINICAL APHERESIS, 2021, 36 (01) : 149 - 160
  • [3] Tissue factor pathway inhibitor: structure-function
    Broze, George J., Jr.
    Girard, Thomas J.
    [J]. FRONTIERS IN BIOSCIENCE-LANDMARK, 2012, 17 : 262 - 280
  • [4] Use of double filtration plasmapheresis for the treatment of acquired thrombocytopenic thrombotic purpura
    Chauvel, Femie
    Reboul, Pascal
    Cariou, Sylvain
    Aglae, Cedric
    Renaud, Sophie
    Trusson, Remi
    Garo, Florian
    Ahmadpoor, Pedram
    Prelipcean, Camelia
    Pambrun, Emilie
    Moranne, Olivier
    [J]. THERAPEUTIC APHERESIS AND DIALYSIS, 2020, 24 (06) : 709 - 717
  • [5] HIGH MOLECULAR-WEIGHT COMPLEX IN HUMAN-PLASMA BETWEEN VITAMIN-K-DEPENDENT PROTEIN-S AND COMPLEMENT COMPONENT C4B-BINDING PROTEIN
    DAHLBACK, B
    STENFLO, J
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1981, 78 (04): : 2512 - 2516
  • [6] More Selective Removal of Myeloperoxidase-Anti-Neutrophil Cytoplasmic Antibody From the Circulation of Patients With Vasculitides Using a Novel Double-Filtration Plasmapheresis Therapy
    Gong, Dehua
    Ji, Daxi
    Xu, Bin
    Liu, Zhihong
    [J]. THERAPEUTIC APHERESIS AND DIALYSIS, 2013, 17 (01) : 93 - 98
  • [7] Double filtration plasmapheresis can decrease factor XIII activity
    Hanafusa, Norio
    Kondo, Yasushi
    Suzuki, Makoto
    Nakao, Akihide
    Noiri, Eisei
    Fujita, Toshiro
    [J]. THERAPEUTIC APHERESIS AND DIALYSIS, 2007, 11 (03) : 165 - 170
  • [8] Double filtration plasmapheresis: Review of current clinical applications
    Hirano, Ryuichiro
    Namazuda, Kenichiro
    Hirata, Noriko
    [J]. THERAPEUTIC APHERESIS AND DIALYSIS, 2021, 25 (02) : 145 - 151
  • [9] Consistent lowering of clotting factors for the treatment of acute cardiovascular syndromes and hypercoagulability: A different pathophysiological approach
    Jaeger, BR
    Goehring, P
    Schirmer, J
    Uhrig, S
    Lohse, P
    Kreuzer, E
    Reichart, B
    Seidel, D
    [J]. THERAPEUTIC APHERESIS, 2001, 5 (04): : 252 - 259
  • [10] Fibrinogen reconstitution after therapeutic apheresis: Comparison of double-filtration plasmapheresis, plasma exchange, and immunoadsorption
    Jouve, Thomas
    Marlu, Raphael
    Naciri Bennani, Hamza
    Noble, Johan
    Chevallier, Eloi
    Motte, Lionel
    Imerzoukene, Farida
    Malvezzi, Paolo
    Rostaing, Lionel
    [J]. JOURNAL OF CLINICAL APHERESIS, 2021, 36 (04) : 574 - 583